Investment bank raises guidance for Novo Nordisk after "impressive" Wegovy launch

An "impressive" launch of Novo Nordisk's new obesity treatment Wegovy has led US investment group Jefferies to increase its expectations for the Danish pharmaceutical company.

BY MARKETWIRE, TRANSLATED BY CATHERINE BRETT

Novo Nordisk's share price target has been increased from USD 66 (DKK 415) to USD 74 (DKK 465) by US investment bank Jeffries after an "impressive" launch, the bank reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Holdings sets sights on more acquisitions in hot bioindustry sector
For subscribers
No needles in sight as Novo succeeds with new capsule technology
For subscribers
ABG hires equity analyst to cover hearing health and pharmaceutical companies
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers

FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.
For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers
Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees
The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.
For subscribers